Download PDF
Aktuelle Neurologie 2002; 29(1): 1-11
DOI: 10.1055/s-2002-20000
Neues in der Neurologie
© Georg Thieme Verlag Stuttgart · New York

Rezeptordarstellung mit der Positronen-Emissions-Tomographie

Anwendung in Klinik und ForschungReceptor Imaging with Positron Emission TomographyP.  Bartenstein1
  • 1Klinik und Poliklinik für Nuklearmedizin, Johannes Gutenberg-Universität Mainz
Further Information

Publication History

Publication Date:
08 February 2002 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Dieser Artikel versucht eine Übersicht über den derzeitigen Stand der Forschung und klinischen Anwendung von PET-Untersuchungen mit Radiopharmaka zu geben, die verschiedene Komponenten der Neurotransmission erfassen sowie über Perspektiven zur künftigen Anwendung der Methodik. Der Fokus wird hierbei auf das GABA/Benzodiazepin-System, das dopaminerge System und das Opiatsystem gelegt. Ausführlich dargestellt werden aktuelle klinische und kliniknahe Anwendungsmöglichkeiten sowie Entwicklungen in der grundlagenorientierten Forschung, die für die künftige Anwendung von PET-Studien mit Rezeptorliganden und anderen Radiopharmaka, die komplexe biochemische Prozesse darstellen, von Bedeutung sein können.

Abstract

This article attemps to review the capabilities and accomplishments of radiotracer imaging with positron emission tomography (PET) in measuring various aspects of neurotransmission with focus on the GABA/benzodiazepine-system, the dopaminergic system and the opiate system. Special emphasis is given to the current status of clinical applications for brain PET studies with specific radiopharmaceuticals and to potential future developments for the use of these methods in basic neuroscience.

Literatur

  • 1 Fahey F H. Positron emission tomography instrumentation.  Radiol Clin North Am. 2001;  39 919-929
    CrossrefPubMedGoogle Scholar
  • 2 Zeki S, Watson J D, Lueck C J. et al . A direct demonstration of functional specialization in human visual cortex.  J Neurosci. 1991;  11 641-649
    PubMedGoogle Scholar
  • 3 Weiller C, May A, Limmroth V. et al . Brain stem activation in spontaneous human migraine attacks.  Nature Med. 1995;  1 658-660
    PubMedGoogle Scholar
  • 4 Zubieta J K, Koeppe R A, Frey K A. et al . Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET.  Synapse. 2001;  39 275-287
    CrossrefPubMedGoogle Scholar
  • 5 Cagnin A, Brooks D J, Kennedy A M. et al . In-vivo measurement of activated microglia in dementia.  Lancet. 2001;  358 461-467
    CrossrefPubMedGoogle Scholar
  • 6 Banati R B, Newcombe J, Gunn R N. et al . The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity.  Brain. 2000;  123 2321-2337
    CrossrefPubMedGoogle Scholar
  • 7 Gerhard A, Neumaier B, Elitok E. et al . In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke.  Neuroreport. 2000;  11 2957-2960
    PubMedGoogle Scholar
  • 8 Halldin C, Gulyas B, Langer O, Farde L. Brain radioligands - state of the art and new trends.  Q J Nucl Med. 2001;  45 139-152
    PubMedGoogle Scholar
  • 9 Bigliani V, Pilowsky L S. In vivo neuropharmacology of schizophrenia.  Br J Psychiatry. 1999;  38, Suppl 23-33
    PubMedGoogle Scholar
  • 10 Lassen N A, Bartenstein P A, Lammertsma A A. et al . Benzodiazepine receptor quantification in vivo in humans using [11C]flumazenil and PET: application of the steady-state principle.  J Cereb Blood Flow Metab. 1995;  15 152-165
    PubMedGoogle Scholar
  • 11 Frost J J, Douglass K H, Mayberg H S. et al . Multicompartmental analysis of [11C]-carfentanil binding to opiate receptors in humans measured by positron emission tomography.  J Cereb Blood Flow Metab. 1989;  9 398-409
    PubMedGoogle Scholar
  • 12 Carson R E, Lang L, Watabe H. et al . PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100 635.  Nucl Med Biol. 2000;  27 493-497
    PubMedGoogle Scholar
  • 13 Logan J, Fowler J S, Volkow N D. et al . Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.  J Cereb Blood Flow Metab. 1990;  10 740-747
    PubMedGoogle Scholar
  • 14 Koeppe R A, Holthoff V A, Frey K A. et al . Compartmental analysis of [11C] flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography.  J Cereb Blood Flow Metab. 1991;  11 735-744
    PubMedGoogle Scholar
  • 15 Cunningham V, Jones T. Spectral analysis of dynamic PET data.  J Cereb Blood Flow Metab. 1993;  13 15-23
    PubMedGoogle Scholar
  • 16 Lammertsma A A, Hume S P. Simplified reference tissue model for PET receptor studies.  Neuroimage. 1996;  4 153-158
    CrossrefPubMedGoogle Scholar
  • 17 Bartenstein P A, Duncan J S, Prevett M C. et al . Investigation of the opioid system in absence seizures with positron emission tomography.  J Neurol Neurosurg Psychiatry. 1993;  56 1295-1302
    CrossrefPubMedGoogle Scholar
  • 18 Koepp M J, Gunn R N, Lawrence A D. et al . Evidence for striatal dopamine release during a video game.  Nature. 1998;  393 266-268
    CrossrefPubMedGoogle Scholar
  • 19 Gründer G, Siessmeier T, Lange-Asschenfeldt C. et al . PET imaging of benzodiazepine receptors in the human brain with F-18 Fluoroethylflumazenil.  Eur J Nucl Med. 2001;  28 1463-1470
    CrossrefPubMedGoogle Scholar
  • 20 Zubieta J K, Smith Y R, Bueller J A. et al . Regional mu opioid receptor regulation of sensory and affective dimensions of pain.  Science. 2001;  293 311-315
    CrossrefPubMedGoogle Scholar
  • 21 Willoch F, Tölle T R, Wester H J. et al . Central pain following pontine infarction is associated with changes in opioid receptor binding: a PET study with C-11 diprenorphine.  Am J Neuroradiol. 1999;  20 145-149
    PubMedGoogle Scholar
  • 22 Olsen R W, Tobin A J. Molecular biology of GABAA-receptors.  FASEB J. 1990;  4 1469-1480
    PubMedGoogle Scholar
  • 23 DeLorey T M, Olsen R W. γ-Aminobutyric acid-A receptor structure and function.  J Biol Chem. 1992;  267 16747-16750
    PubMedGoogle Scholar
  • 24 Beer H F, Bläuenstein P A, Hasler P H. et al . In vitro and in vivo evaluation of Iodine-123-Ro 16-0154: A new imaging agent for SPECT investigations of benzodiazepine receptors.  J Nucl Med. 1990;  31 1007-1014
    PubMedGoogle Scholar
  • 25 Bartenstein P, Ludolph A, Schober O. et al . Benzodiazepine receptors and cerebral blood flow in partial epilepsy.  Eur J Nucl Med. 1991;  18 111-118
    PubMedGoogle Scholar
  • 26 Maziere M, Hantraye P, Prenant C. et al . Synthesis of ethyl 8-Fluoro-5,6-dihydroxy-5-[11C]methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography.  Int J Appl Radiat Isot. 1984;  35 973-976
    CrossrefPubMedGoogle Scholar
  • 27 Comar D, Maziere M, Godot J M. et al . Visualization of 11C-flunitrazepam displacement in the brain of the life baboon.  Nature. 1979;  280 329-331
    PubMedGoogle Scholar
  • 28 Frost J J, Wagner H N, Dannals R F. et al . Imaging benzodiazepine receptors in man with 11C-suriclone by positron emission tomography.  Eur J Pharmacol. 1986;  122 381-383
    CrossrefPubMedGoogle Scholar
  • 29 Johnström P, Duelfer T, Stone-Elander S. et al . Synthesis of the benzodiazepine-1 antagonist 18F-2-oxoquazepam.  J Label Compound Radiopharm. 1988;  26 334-335
    PubMedGoogle Scholar
  • 30 Atack J R, Smith A J, Emms F, McKernan R M. Regional differences in the inhibition of mouse in vivo [3H]Ro 15-1788 binding reflect selectivity for alpha 1 versus alpha 2 and alpha 3 subunit-containing GABAA receptors.  Neuropsychopharmacology. 1999;  20 255-262
    CrossrefPubMedGoogle Scholar
  • 31 Moerlein S M. N-w-[F-18]Fluoroalcylated flumazenil: potential agents for mapping cerebral benzodiazepine receptors with PET.  J Nucl Med. 1990;  31 902-906
    PubMedGoogle Scholar
  • 32 Munz F, Ludwig T, Ziegler S. et al .Performance assessment of parallel spectral analysis: Towards a practical performance model for parallel medical applications. Proceedings of the 7th International Conference on High Performance Computing and Networking, Europe Lecture notes in computer science 1539. Berlin; Springer 1999: 430-439
    Google Scholar
  • 33 Kuwert T, Bartenstein P, Grünwald F. et al . Klinische Wertigkeit der Positronen-Emissions-Tomographie in der Neuromedizin: Positionspapier zu den Ergebnissen einer interdisziplinären Konsensuskonferenz.  Nervenarzt. 1998;  69 1045-1060
    CrossrefPubMedGoogle Scholar
  • 34 Arnold S, Berthele A, Drzezga A. et al . Reduction of benzodiazepine receptor binding is related to the seizure onset zone in extratemporal focal cortical dysplasia.  Epilepsia. 2000;  41 818-824
    PubMedGoogle Scholar
  • 35 Henry T R, Frey K A, Sackellares J C. et al . In vivo cerebral metabolism and central benzodiazepine-receptor binding in temporal lobe epilepsy.  Neurology. 1993;  43 1998-2006
    PubMedGoogle Scholar
  • 36 Savic I, Thorell J O, Roland P. [11C]flumazenil positron emission tomography visualizes frontal epileptogenic regions.  Epilepsia. 1995;  36 1225-1232
    CrossrefPubMedGoogle Scholar
  • 37 Koepp M J, Hammers A, Labbe C. et al . 11C-flumazenil PET in patients with refractory temporal lobe epilepsy and normal MRI.  Neurology. 2000;  54 332-339
    CrossrefPubMedGoogle Scholar
  • 38 Koutroumanidis M, Binnie C D, Elwes R D. et al . Interictal regional slow activity in temporal lobe epilepsy correlates with lateral temporal hypometabolism as imaged with 18FDG PET: neurophysiological and metabolic implications.  J Neurol Neurosurg Psychiatry. 1998;  65 170-176
    PubMedGoogle Scholar
  • 39 Sadzot B, Debets R M, Delfiore G. et al . C-11-Flumazenil Positron emission tomography: An in vivo marker of neuronal loss in temporal lobe epilepsy.  Epilepsia. 1994;  35, Suppl 7 S28
    PubMedGoogle Scholar
  • 40 Hammers A, Koepp M J, Richardson M P. et al . Central benzodiazepine receptors in malformations of cortical development: A quantitative study.  Brain. 2001;  124 1555-1565
    CrossrefPubMedGoogle Scholar
  • 41 Hammers A, Koepp M J, Labbe C. et al . Neocortical abnormalities of [11C]-flumazenil PET in mesial temporal lobe epilepsy.  Neurology. 2001;  56 897-906
    PubMedGoogle Scholar
  • 42 Winkler P A, Herzog C, Henkel A. et al . Nichtinvasives Protokoll für die epilepsiechirurgische Behandlung fokaler Epilepsien.  Nervenarzt. 1999;  70 1088-1093
    CrossrefPubMedGoogle Scholar
  • 43 Juhasz C, Chugani D C, Muzik O. et al . Relationship of flumazenil and glucose PET abnormalities to neocortical epilepsy surgery outcome.  Neurology. 2001;  56 1650-1658
    CrossrefPubMedGoogle Scholar
  • 44 Bartenstein P, Grünwald F, Kuwert T. et al . Klinische Anwendungen der Single-Photon-Emissionstomographie in der Neuromedizin 1: Neuroonkologie, Epilepsien, Basalganglienerkrankungen, zerebrovaskuläre Erkrankungen.  Nuklearmedizin. 2000;  39 180-195
    PubMedGoogle Scholar
  • 45 Odano I, Miyashita K, Minoshima S. et al . A potential use of a 123I-labelled benzodiazepine receptor antagonist as a predictor of neuronal cell viability: comparisons with 14C-labelled 2-deoxyglucose autoradiography and histopathological examination.  Nucl Med Commun. 1995;  16 443-446
    PubMedGoogle Scholar
  • 46 Heiss W D, Kracht L, Grond M. et al . Early C-11 flumazenil/H2O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy.  Stroke. 2000;  31 366-369
    PubMedGoogle Scholar
  • 47 Lloyd C M, Richardson M P, Brooks D J. et al . Extramotor involvement in ALS: PET studies with the GABA(A) ligand C-11 flumazenil.  Brain. 2000;  123 2289-2296
    CrossrefPubMedGoogle Scholar
  • 48 Foster N L, Minoshima S, Johanns J. et al . PET measures of benzodiazepine receptors in prograssive supranuclera palsy.  Neurology. 2000;  54 1768-1773
    PubMedGoogle Scholar
  • 49 Macdonald G A, Frey K A, Agranoff B W. et al . Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepathic encephalopathy.  Hepatology. 1997;  26 277-282
    CrossrefPubMedGoogle Scholar
  • 50 Jalan R, Turjanski N, Taylor Robinson S D. et al .Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. 
    Google Scholar
  • 51 Malizia A L, Cunningham V J, Bell C J. et al . Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET-study.  Arch Gen Psychiatry. 1998;  55 715-720
    PubMedGoogle Scholar
  • 52 Abi-Dargham A, Krystal J H, Anjilvel S. et al . Alterations of benzodiazepine receptors in type II alcoholic subjects measured with SPECT and I-123 iomazenil.  Am J Psychiatry. 1998;  155 1550-1555
    PubMedGoogle Scholar
  • 53 Garnett E S, Firnau G, Chan P K. et al . [18F]fluoro-dopa, an analogue of dopa, and its use in direct external measurements of storage, degradation, and turnover of intracerebral dopamine.  Proc Natl Acad Sci USA. 1978;  75 464-467
    PubMedGoogle Scholar
  • 54 Brooks D J. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease.  J Neurol. 2000;  247, Suppl 2 II11-18
    PubMedGoogle Scholar
  • 55 Melega W P, Luxen A, Perlmutter M M. et al . Comparative in vivo metabolism of 6-[18F]fluoro-L-dopa and [3H]L-dopa in rats.  Biochem Pharmacol. 1990;  15, 39 1853-1860
    PubMedGoogle Scholar
  • 56 Heiss W D, Würker M. Möglichkeiten und Grenzen funktioneller bildgebender Verfahren beim Parkinson-Syndrom.  Nervenarzt. 1999;  70, Suppl 1 S2-10
    CrossrefPubMedGoogle Scholar
  • 57 Tatsch K. Imaging of the dopaminergic system in parkinsonism with SPET.  Nucl Med Commun. 2001;  22 819-827
    CrossrefPubMedGoogle Scholar
  • 58 Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review.  J Cereb Blood Flow Metab. 2000;  20 423-451
    PubMedGoogle Scholar
  • 59 Mukherjee J, Yang Z Y, Brown T. et al . Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride.  Nucl Med Biol. 1999;  26 519-527
    PubMedGoogle Scholar
  • 60 Gründer G, Siessmeier T, Piel M. et al . Spectral analysis of [18F]desmethoxyfallypride binding to human D2-like dopamine receptors.  Neuroimage. 2000;  11 S33
    CrossrefPubMedGoogle Scholar
  • 61 Coenen H H, Laufer P, Stöcklin G. et al . 3-N-(2-[18F]-fluoroethyl)-spiperone: a novel ligand for cerebral dopamine receptor studies with PET.  Life Sci. 1987;  40 81-88
    CrossrefPubMedGoogle Scholar
  • 62 Fowler J S, Volkow N D, Wang G J. et al . Inhibition of monoamine oxidase B in the brains of smokers.  Nature. 1996;  379 733-736
    CrossrefPubMedGoogle Scholar
  • 63 Piccini P, Burn D J, Ceravolo R. et al . The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins.  Ann Neurol. 1999;  45 577-582
    CrossrefPubMedGoogle Scholar
  • 64 Brooks D J, Ibanez V, Sawle G V. et al . Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.  Ann Neurol. 1990;  28 547-555
    CrossrefPubMedGoogle Scholar
  • 65 Barker R A, Dunnett S B. Functional integration of neural grafts in Parkinson's disease.  Nat Neurosci. 1999;  2 1047-1048
    CrossrefPubMedGoogle Scholar
  • 66 Antonini A, Leenders K L, Vontobel P. et al . Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.  Brain. 1997;  120 2187-2195
    CrossrefPubMedGoogle Scholar
  • 67 Perlmutter J S, Kilbourn M R, Raichle M E, Welch M J. MPTP-induced up-regulation of in vivo dopaminergic radioligand-receptor binding in humans.  Neurology. 1987;  37 1575-1579
    PubMedGoogle Scholar
  • 68 Verhoeff N P. Radiotracer imaging of dopaminergic transmission in neuropsychiatric disorders.  Psychopharmacology. 1999;  147 217-249
    CrossrefPubMedGoogle Scholar
  • 69 Breier A, Su T P, Saunders R. et al . Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.  Proc Natl Acad Sci USA. 1997;  94 2569-2574
    CrossrefPubMedGoogle Scholar
  • 70 Volkow N D, Wang G J, Fowler J S. et al . Imaging endogenous dopamine competition with [11C]raclopride in the human brain.  Synapse. 1994;  16 255-262
    CrossrefPubMedGoogle Scholar
  • 71 Koepp M J, Duncan J S. PET: Opiate receptor mapping. In: Henry TR, Duncan JS, Berkovic SF (eds) Functional imaging in the epilepsies. Philadelphia; Lippincott Williams & Wilkins 2000: 145-156
    Google Scholar
  • 72 Pfeiffer A, Pasi A, Mehraein P, Herz A. Opiate receptor binding sites in human brain.  Brain Res. 1982;  248 87-96
    CrossrefPubMedGoogle Scholar
  • 73 Pasternak G W, Wood P J. Multiple Mu opiate receptors.  Life Sci. 1986;  38 1889-1898
    CrossrefPubMedGoogle Scholar
  • 74 Chavkin C, Shoemaker W J, McGinty J F. et al . Characterization of the prodynorphin and proenkephalin neuropeptide systems in rat hippocampus.  J Neurosci. 1985;  5 808-816
    PubMedGoogle Scholar
  • 75 Zieglgänsberger W, French E D, Siggins G R, Bloom F E. Opioid peptides may excite hippocampal pyramidal neurons by inhibiting adjacent inhibitory interneurons.  Science. 1979;  205 415-417
    PubMedGoogle Scholar
  • 76 Jones A K, Luthra S K, Maziere B. et al . Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers.  J Neurosci Methods. 1988;  23 121-129
    CrossrefPubMedGoogle Scholar
  • 77 Frost J J, Mayberg H S, Fisher R S. et al . Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy.  Ann Neurol. 1988;  23 231-237
    CrossrefPubMedGoogle Scholar
  • 78 Wester H J, Willoch F, Tölle T R. et al . 6-O-(2-[18F]fluoroethyl)-6-O-desmethyldiprenorphine ([18F]DPN): synthesis, biologic evaluation, and comparison with [11C]DPN in humans.  J Nucl Med. 2000;  41 1279-1286
    PubMedGoogle Scholar
  • 79 Lever J R, Ilgin N, Musachio J L. et al . Autoradiographic and SPECT imaging of cerebral opioid receptors with an iodine-123 labeled analogue of diprenorphine.  Synapse. 1998;  29 172-182
    CrossrefPubMedGoogle Scholar
  • 80 Dannals R F, Ravert H T, Frost J J. et al . Radiosynthesis of an opiate receptor binding radiotracer: [11C]Carfentanil.  Int J Appl Radiat Isot. 1985;  36 303-306
    CrossrefPubMedGoogle Scholar
  • 81 Madar I, Lever J R, Kinter C M. et al . Imaging of delta opioid receptors in human brain by N1'-([11C]methyl)naltrindole and PET.  Synapse. 1996;  24 19-28
    CrossrefPubMedGoogle Scholar
  • 82 Theodore W H, Carson R E, Andreasen P. et al . PET imaging of opiate receptor binding in human epilepsy using [18F]cyclofoxy.  Epilepsy Res. 1992;  13 129-139
    CrossrefPubMedGoogle Scholar
  • 83 Smith J S, Zubieta J K, Price J C. et al . Quantification of delta-opioid receptors in human brain with N1'-([11C]methyl) naltrindole and positron emission tomography.  J Cereb Blood Flow Metab. 1999;  19 956-966
    PubMedGoogle Scholar
  • 84 Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions aof multiple opiate and non-opiate systems.  Brain Res Rev. 1983;  6 197-210
    CrossrefPubMedGoogle Scholar
  • 85 Kelsley J E, Belluzi J D. Endorphin mediation of post-ictal effects of kindled seizures in rats.  Brain Res. 1982;  253 337-340
    CrossrefPubMedGoogle Scholar
  • 86 Savage D D, Mills S A, Jobe P C, Reigel C E. Elevation of naloxone-sensitive 3H-dihydromorphine binding in hippocampal formation of genetically epilepsy-prone rats.  Life Sci. 1988;  43 239-246
    CrossrefPubMedGoogle Scholar
  • 87 Mayberg H S, Sadzot B, Meltzer C C. et al . Quantification of mu and non-mu opiate receptors in temporal lobe epilepsy using positron emission tomography.  Ann Neurol. 1991;  30 3-11
    CrossrefPubMedGoogle Scholar
  • 88 Bartenstein P A, Prevett M C, Duncan J S. et al . Quantification of opiate receptors in two patients with mesiobasal temporal lobe epilepsy, before and after selective amygdalohippocampectomy, using positron emission tomography.  Epilepsy Res. 1994;  18 119-125
    CrossrefPubMedGoogle Scholar
  • 89 Madar I, Lesser R P, Krauss G. et al . Imaging of delta- and mu-opioid receptors in temporal lobe epilepsy by positron emission tomography.  Ann Neurol. 1997;  41 358-367
    CrossrefPubMedGoogle Scholar
  • 90 Urca G, Frenk H, Liebeskind J C. et al . Morphine and enkephalin - analgesic and epileptic properties.  Science. 1977;  197 83-86
    PubMedGoogle Scholar
  • 91 Albertson T E, Joy R M, Stark L G. Modification of kindled amygdaloid seizures by opiate agonists and antagonists.  J Pharmacol Exp Ther. 1984;  228 620-627
    PubMedGoogle Scholar
  • 92 Koepp M J, Richardson M P, Brooks D J, Duncan J S. Focal cortical release of endogenous opioids during reading-induced seizures.  Lancet. 1998;  352 952-955
    CrossrefPubMedGoogle Scholar
  • 93 Treede R D, Kenshalo D R, Gracely R H, Jones A K. The cortical representation of pain.  Pain. 1999;  79 105-111
    CrossrefPubMedGoogle Scholar
  • 94 Jones A K, Liyi Q, Cunningham V V. et al . Endogenous opiate response to pain in rheumatoid arthritis and cortical and subcortical response to pain in normal volunteers using positron emission tomography.  Int J Clin Pharmacol Res. 1991;  11 261-266
    PubMedGoogle Scholar
  • 95 Jones A K, Kitchen N D, Watabe H. et al . Measurement of changes in opioid receptor binding in vivo during trigeminal neuralgic pain using [11C] diprenorphine and positron emission tomography.  J Cereb Blood Flow Metab. 1999;  19 803-808
    PubMedGoogle Scholar
  • 96 Carter B D, Medzihradsky F. Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells.  Mol Pharmacol. 1993;  43 465-473
    PubMedGoogle Scholar
  • 97 Uhl G R, Sora I, Wang Z. The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses.  Proc Natl Acad Sci USA. 1999;  96 7752-7755
    CrossrefPubMedGoogle Scholar
  • 98 Weeks R A, Cunningham V J, Piccini P. et al . 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping.  J Cereb Blood Flow Metab. 1997;  17 943-949
    PubMedGoogle Scholar
  • 99 Piccini P, Weeks R A, Brooks D J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias.  Ann Neurol. 1997;  42 720-726
    CrossrefPubMedGoogle Scholar
  • 100 Cohen R M, Andreason P J, Doudet D J. et al . Opiate receptor avidity and cerebral blood flow in Alzheimer's disease.  J Neurol Sci. 1997;  148 171-180
    CrossrefPubMedGoogle Scholar
  • 101 Albin R L, Reiner A, Anderson K D. et al . Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease.  Ann Neurol. 1992;  31 425-430
    CrossrefPubMedGoogle Scholar
  • 102 Turjanski N, Weeks R, Dolan R. et al . Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.  Brain. 1995;  118 689-696
    CrossrefPubMedGoogle Scholar
  • 103 Kling M A, Carson R E, Borg L. et al . Opioid receptor imaging with positron emission tomography and [(18)F]cyclofoxy in long-term, methadone-treated former heroin addicts.  J Pharmacol Exp Ther. 2000;  295 1070-1076
    PubMedGoogle Scholar
  • 104 Heinz A, Reimold M, Hermann D. et al . Craving and relapse are associated with µ-opioid availability in alcoholics a C-11 carfentanil study.  J Nucl Med. 2001;  42 107
    PubMedGoogle Scholar
  • 105 Willoch F, Schütz C, Wester H J. et al . Opioid receptor binding changes in alcohol dependent males during detoxification and in comparison to control.  J Nucl Med. 1999;  40 111
    PubMedGoogle Scholar
  • 106 Zubieta J K, Gorelick D A, Stauffer R. et al . Increased mu opioid receptor binding detected by PET in cocaine-dependent man is associated with cocaine craving.  Nature Med. 1996;  2 1225-1229
    PubMedGoogle Scholar
  • 107 Zubieta J K, Dannals R F, Frost J J. Gender and age influences on human brain mu-opioid receptor binding measured by PET.  Am J Psychiatry. 1999;  156 842-848
    PubMedGoogle Scholar
  • 108 Smith Y R, Zubieta J K, del Carmen M G. et al . Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones.  J Clin Endocrinol Metab. 1998;  83 4498-4505
    CrossrefPubMedGoogle Scholar
  • 109 Stöcklin G L. Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)?.  Eur J Nucl Med. 1998;  25 1612-1616
    PubMedGoogle Scholar

Prof. Dr. med. P. Bartenstein

Klinik und Poliklinik für Nuklearmedizin · Johannes Gutenberg-Universität Mainz

Langenbeckstraße 1

55101 Mainz

Email: Bartenstein@nuklear.klinik.uni-mainz.de

      >